<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591200</url>
  </required_header>
  <id_info>
    <org_study_id>SRPL/LC/09-10/001</org_study_id>
    <nct_id>NCT01591200</nct_id>
  </id_info>
  <brief_title>Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis</brief_title>
  <official_title>A Parallel Group Randomized Open Blinded End Point Evaluation, Multicentric, Dose Escalation, Phase -II Study Assessing the Safety and Efficacy of Intraarterial (Hepatic) Ex-vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Alcoholic Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stempeutics Research Pvt Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stempeutics Research Pvt Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of mesenchymal stem cells in patients with
      cirrhosis of liver. Stem cells will be injected into the hepatic artery. Improvement in
      various parameters will be observed over 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>2 years</time_frame>
    <description>The type of adverse events, number of adverse events and proportion of patients with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver function tests.</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the improvement in liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT scan of abdomen.</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the improvement in liver structure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MELD score</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the clinical improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life as assessed by SF 36 questionnaire</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the improvement in quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological evaluation of liver biopsy by immunohistochemical staining for AFP, PCNA, SMA</measure>
    <time_frame>6 Months</time_frame>
    <description>To assess the improvement in histopathology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Child-Pugh score</measure>
    <time_frame>2 years</time_frame>
    <description>To assess clinical improvement</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Alcoholic Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will receive standard protocol of care alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem cells high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive high dose of Allogeneic Mesenchymal Stem Cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem cells intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive intermediate dose of Allogeneic Mesenchymal Stem Cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem cells low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive low dose of Allogeneic Mesenchymal Stem Cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Stem Cells</intervention_name>
    <description>High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery</description>
    <arm_group_label>Stem cells high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Stem Cells</intervention_name>
    <description>Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery</description>
    <arm_group_label>Stem cells intermediate dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Stem Cells</intervention_name>
    <description>Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery</description>
    <arm_group_label>Stem cells low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Alcoholic cirrhotics between 18-65 years of age (diagnosed by clinical, biochemical,
             sonographic, radiological [CT scan] or histological evidence of cirrhosis and portal
             hypertension).

          -  Evidence of decompensated liver disease at screening (e.g. Child class B or C,
             Child-Pugh scores of â‰¥7 and &lt;14).

          -  MELD scores of at least 10 (UNOS Meld calculator).

          -  Normal AFP Level

          -  Hb&gt;10gm/dl.

          -  Female patients of childbearing age must be willing to use accepted methods of
             contraception during the course of the study

          -  Signed informed consent.

        Exclusion Criteria:

          -  Patients likely to undergo liver transplantation during the duration of the study.

          -  Presence of advanced hepatic encephalopathy Grades 3 &amp; 4 (West Haven criteria for
             grading of hepatic encephalopathy) at the time of screening

          -  Active variceal bleed.

          -  Refractory ascites.

          -  Evidences of autoimmune liver disease- ANA or Anti-LKM positivity.

          -  Platelet count &lt; 30,000/mm3.

          -  Serum Sodium &lt;129mEq/L.

          -  Serum Creatinine &gt; 2 mg/dl.

          -  Hepatocellular carcinoma or other malignancies

          -  Active infectious disease.

          -  Presence of severe underlying cardiac, pulmonary or renal disease.

          -  Excessive alcohol (&gt;30 gm of alcohol/day) use in the last 3 months before screening.

          -  Positive HbSAg or antibodies to HIV or HCV.

          -  Pregnancy or lactation.

          -  Participation in other clinical trials.

          -  Unwilling/unable to sign the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. BV Tantry, MD., DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>KMC, Mangalore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Samir Shah, MD., DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Breach Candy Hospital, Mumbai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Dinesh Kini, MD., DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manipal Hospital, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr.Deepak N Amarapuraka, MD., DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bombay Hospital &amp; Medical Research Center, Mumbai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. VA Saraswat, MD., DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGPGI, Kucknow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Aejaz Habeeb, MD., DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Liver Research &amp; Diagnostics, Hyderabad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Uma Devi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mediciti Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Sanjay Kolte Kolte, DNB., FCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahyadri Speciality Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Sandeep Nijhwan Nijhwan, MD., DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMS Medical College and Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Nitin Pai, MD., DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruby Hall clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Liver Research &amp; Diagnostics</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500058</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediciti Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manipal Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KMC Hospital</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of liver disease, HPB surgery and transplant Global Hospitals</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bombay Hospital &amp; Medical Research Center</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall clinic</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahyadri Speciality Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMS Medical college and Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SGPGI Lucknow</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2012</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcoholic</keyword>
  <keyword>Liver</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Stem</keyword>
  <keyword>Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

